In a highly anticipated decision, a federal court has ruled on the contentious issue of mail-order access to the abortion medication mifepristone. The ruling comes after weeks of uncertainty, leaving many patients and healthcare providers in limbo. The controversy centers around the medication's availability by mail, which some argue is a crucial option for those living in areas with limited access to reproductive healthcare services. The court's decision is expected to have significant implications for women's reproductive rights and access to essential medical care.
The ruling came after weeks of uncertainty over mail order mifepristone's legal status
